ADARx Pharmaceuticals Inc.

Our vision is to provide effective and safe therapeutics to patients who suffer from intractable diseases.

General Information
Company Name
ADARx Pharmaceuticals Inc.
Founded Year
2019
Location (Offices)
San Diego, United States +1
Founders / Decision Makers
Number of Employees
69
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series C
Social Media

ADARx Pharmaceuticals Inc. - Company Profile

ADARx Pharmaceuticals Inc. is a San Diego-based biotechnology company with a vision to provide effective and safe therapeutics for patients suffering from intractable diseases. The company specializes in developing proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibiting, degrading, and editing disease-causing mRNA. With a focus on genetic, cardiometabolic, complement-mediated, and central nervous system diseases, ADARx has a growing pipeline of RNA targeting therapeutics. Established in 2019, the company has secured significant funding from a syndicate of renowned VC firms, including HBM Healthcare Investments, BlackRock, Vivo Capital, Marshall Wace, Redmile Group, T. Rowe Price, Cormorant Asset Management, SR One, Venrock Healthcare Capital Partners, and Bain Capital Life Sciences. Their most recent Series C investment of $200.00M was received on 09 August 2023. ADARx's multiple active programs in development, including a lead candidate in the clinical stage, position the company as an innovative player in the biotechnology and pharmaceutical industries, with the potential to make a significant impact on the healthcare sector.

Taxonomy: RNA targeting, therapeutics, genetic medicine, clinical stage, oligonucleotide delivery, gene editing, cardiometabolic diseases, complement-mediated diseases, central nervous system diseases, ADAR technology, mRNA base editing, clinical trials, VC funding, San Diego

Funding Rounds & Investors of ADARx Pharmaceuticals Inc. (5)

View All
Funding Stage Amount No. Investors Investors Date
Series C $200.00M 10 Bain Capital Life Sciences 09 Aug 2023
Series B $46.00M - 20 Jan 2023
Series B $75.00M - 08 Sep 2021
Venture Round $6.00M - 12 Nov 2020
Seed Round $5.00M - 04 Aug 2020

Latest News of ADARx Pharmaceuticals Inc.

View All

No recent news or press coverage available for ADARx Pharmaceuticals Inc..

Similar Companies to ADARx Pharmaceuticals Inc.

View All
Sanegene Bio - Similar company to ADARx Pharmaceuticals Inc.
Sanegene Bio Dedicated to developing novel life-changing RNAi therapeutics
Seelos Therapeutics, Inc. - Similar company to ADARx Pharmaceuticals Inc.
Seelos Therapeutics, Inc. A clinical-stage biopharmaceutical company focused on central nervous system disorders and rare diseases.
Vera Therapeutics, Inc. - Similar company to ADARx Pharmaceuticals Inc.
Vera Therapeutics, Inc. We are a clinical-stage biotechnology company developing treatments that transform patients’ lives.
Atriva Therapeutics GmbH - Similar company to ADARx Pharmaceuticals Inc.
Atriva Therapeutics GmbH Clinical stage biopharmaceutical company spearheading antiviral drug innovation
OliX Pharmaceuticals, Inc. - Similar company to ADARx Pharmaceuticals Inc.
OliX Pharmaceuticals, Inc. Contributing to the Health and Happiness of Mankind with RNAi Technology